NASDAQ$IDYA

IDEAYA Biosciences Inc · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Headline financials

Total Revenue

$4.02M

Previous: $2.96M+35.7%
EPS (adj)

-$0.50

Previous: -$0.47-6.4%
Free Cash Flow

-$23.4M

Previous: -$17.3M-35.4%
Net Income

-$22M

Previous: -$18.2M-20.6%
Operating Income

-$26.4M

Previous: -$18.4M-44.0%
Gross Profit

$3.46M

Previous: $2.54M+36.5%
Cash & Equivalents

$68.6M

Previous: $92M-25.4%
Total Assets

$388M

Previous: $381M+1.7%
Stock-Based Comp

$2.98M

Previous: $2.06M+44.1%

Revenue & EPS history

IDEAYA · Revenue · Quarterly

$4.02M

Q4 2022+35.7%vs Q4 2021
Beat estimate in 6 of 15 quarters(40%)
ActualEstimate

Revenue by segment

IDEAYA · $8.04M total across 1 segment · Q3 2023

  • Collaboration Revenue
    $8.04M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

+1.4%

Avg return

Earnings day

+2.1%

Avg return

5 days after

+6.7%

Avg return

30 days after

52%

14 / 27 earnings

Positive

+40.5%

Q3 2019

Best reaction

-31.4%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.3%-1.9%+1.2%
Q4 2025+1.6%+5.6%+7.7%
Q3 2025-2.7%-3.6%+14.8%
Q1 2025+2.9%+10.6%+28.1%
Q4 2024-5.4%-6.9%-15.4%
Q3 2024+3.4%+9.4%-0.9%
Q2 2024-3.1%+2.4%+1.0%
Q1 2024-3.9%-4.5%-8.0%
Q4 2023-6.0%-2.7%-3.2%
Q3 2023+6.9%+1.6%+8.1%
Q2 2023+1.2%+3.3%+12.9%
Q1 2023+15.6%+10.2%+31.5%
Q4 2022+2.1%-8.7%-16.0%
Q3 2022-3.4%-1.8%-2.5%
Q2 2022-31.4%-34.8%-20.1%
Q1 2022+13.0%+26.4%+48.4%
Q4 2021-2.2%+3.8%-11.1%
Q3 2021+3.9%+0.8%-4.1%
Q2 2021-3.5%+1.0%+14.1%
Q1 2021+7.8%+1.7%+12.5%
Q4 2020-8.2%-2.8%-15.9%
Q3 2020+2.5%+6.3%+9.3%
Q2 2020-1.2%-1.7%+4.8%
Q1 2020-9.4%-0.6%-5.3%
Q4 2019+13.6%+14.9%+40.8%
Q3 2019+40.5%+30.6%+29.6%
Q2 2019+6.0%-1.5%+19.6%
Q1 2019
Q4 2018
Q3 2018
Q2 2018
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro